GILLIAN ZEILE
Prescription History 1013378124
Nurse Practitioner - Adult Health in Pittsburgh, PA


Quality Rating: 78.53 out of 100 score

NPI Status: Active since March 16, 2016

Contact Information

9100 BABCOCK BLVD # 5135
PITTSBURGH, PA
ZIP 15237
Phone: (412) 748-5790

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for GILLIAN ZEILE, an active Adult Health specialist practicing in Pittsburgh, PA. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 154 documented patient claims. Among these therapy options, the most frequently utilized medication is Letrozole, which accounts for 104 claims alone.

Medication Index

No matching medications currently found on file.

Eliquis

Generic Formulation: ApixabanSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 19
30-Day Fills 35.0
Days Supply 1,050
PA State Average Benchmarks
Peer Average Claims92.0
Peer Average 30-Day Fills137.0
Peer Average Days Supply3,769
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 79.3% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $18,553.03 across this reporting matrix range.

Provider Avg Cost Per Claim

$976.48

State Avg Cost Per Claim

$730.59

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Letrozole

Generic Formulation: LetrozoleSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 104
30-Day Fills 291.0
Days Supply 8,730
PA State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills100.1
Peer Average Days Supply2,980
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 126.1% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,195.37 across this reporting matrix range.

Provider Avg Cost Per Claim

$40.34

State Avg Cost Per Claim

$26.83

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Morphine Sulfate Er

Generic Formulation: Morphine SulfateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 420
PA State Average Benchmarks
Peer Average Claims43.0
Peer Average 30-Day Fills44.1
Peer Average Days Supply1,260
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 67.4% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $461.55 across this reporting matrix range.

Provider Avg Cost Per Claim

$32.97

State Avg Cost Per Claim

$45.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle.

Therapeutic Applications

This medication is used to treat severe pain. Morphine belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Oxycodone Hcl

Generic Formulation: Oxycodone HclSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 387
PA State Average Benchmarks
Peer Average Claims54.0
Peer Average 30-Day Fills54.4
Peer Average Days Supply1,033
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 68.5% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $719.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$42.31

State Avg Cost Per Claim

$22.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic derivative of CODEINE.

Therapeutic Applications

This medication is used to help relieve moderate to severe pain. Oxycodone belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like GILLIAN ZEILE provides transparency into local medical care patterns within Pittsburgh, PA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Adult Health** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.